Tegavivint
CTNNB1-Related Neurodevelopmental Disorder And/Or Vitreoretinopathy
Explore 1 assets in CTNNB1-Related Neurodevelopmental Disorder And/Or Vitreoretinopathy →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
HonorHealth Research Institute
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07463599CT.gov Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · CTNNB1-Related Neurodevelopmental Disorder And/Or Vitreoretinopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tegavivint (this asset) | HonorHealth Research Institute | P1/2 | CCC · 48 |
Other indications for Tegavivint
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Endometrial Carcinoma | — | P1/2 | CCC · 48 |
| Desmoid Tumor | — | P1/2 | CCC · 48 |
| Ewing Sarcoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Tegavivint in CTNNB1-Related Neurodevelopmental Disorder And/Or Vitreoretinopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tegavivint-ctnnb1-related-neurodevelopmental-disorder-andor-vitreoretinopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →